Jump to main content
Jump to site search

Issue 26, 2013
Previous Article Next Article

Macromolecular prodrugs of ribavirin combat side effects and toxicity with no loss of activity of the drug

Author affiliations

Abstract

Chemi-enzymatic synthesis of ribavirin acrylate and subsequent RAFT co-polymerization with acrylic acid afforded a formulation of a broad spectrum antiviral drug which avoids accumulation in erythrocytes, the origin of the main side effect of ribavirin. In cultured macrophages the macromolecular prodrugs exhibited decreased toxicity while maintaining the anti-inflammatory action of ribavirin.

Graphical abstract: Macromolecular prodrugs of ribavirin combat side effects and toxicity with no loss of activity of the drug

Back to tab navigation

Supplementary files

Publication details

The article was received on 14 Jan 2013, accepted on 07 Feb 2013 and first published on 08 Feb 2013


Article type: Communication
DOI: 10.1039/C3CC00315A
Citation: Chem. Commun., 2013,49, 2643-2645
  •   Request permissions

    Macromolecular prodrugs of ribavirin combat side effects and toxicity with no loss of activity of the drug

    M. B. L. Kryger, B. M. Wohl, A. A. A. Smith and A. N. Zelikin, Chem. Commun., 2013, 49, 2643
    DOI: 10.1039/C3CC00315A

Search articles by author

Spotlight

Advertisements